Microsoft PowerPoint - 18_Main_Summary-Conclusion_ver1-9.ppt - Telithromycin - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2007-01-16 14:32:21 Imidazoles Pyridines Telithromycin Pathogenic bacteria Antibiotic resistance Biology Macrolide Quinolone Solithromycin Medicine Antibiotics Health		Microsoft PowerPoint - 18_Main_Summary-Conclusion_ver1-9.ppt Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 67,64 KB Share Document on Facebook

	South Dakota State Employee Benefits Program Non-Covered Products under Pharmacy Benefits  Adasuve®  Emergency Contraception Agents DocID: 1oJv5 - View Document
	LACK OF DEVELOPEMENT OF NEW ANTIBIOTICS: WHO SHOULD BE BLAMED AND WHAT CAN BE DONE? S. Ragnar Norrby Swedish Institute for Infectious DocID: 16pVU - View Document
	Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Report 1:b:ii Benefit - Risk Wave 1 Case Study Report: Ketek® DocID: 11eWT - View Document
	Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID[removed], 7 pages http://dx.doi.org[removed][removed]Research Article DocID: O0Uy - View Document
	August 21, 2006 sanofi-aventis K.K. Astellas Pharma Inc. DISCONTINUATION OF MARKETING ALLIANCE ON KETOLIDE ANTIBIOTICS, “KETEK® TABLETS 300MG” DocID: LYow - View Document